tiprankstipranks
Advertisement
Advertisement

AU:PYC Stock Latest News

PYC Therapeutics Earns Buy Rating on Strong Early Safety Profile and Dose Escalation Support for PYC-003 in ADPKD
RatingsPYC Therapeutics Earns Buy Rating on Strong Early Safety Profile and Dose Escalation Support for PYC-003 in ADPKD
8d ago
PYC Therapeutics advances genetic disease pipeline and strengthens corporate footing
PremiumCompany Announcements
PYC Therapeutics advances genetic disease pipeline and strengthens corporate footing
16d ago
PYC Therapeutics Gains Safety Clearance to Escalate Dosing in PKD Trial
PremiumCompany Announcements
PYC Therapeutics Gains Safety Clearance to Escalate Dosing in PKD Trial
23d ago
PYC Therapeutics Secures Shareholder Approval at Extraordinary General Meeting
PremiumCompany Announcements
PYC Therapeutics Secures Shareholder Approval at Extraordinary General Meeting
30d ago
PYC Therapeutics Wins Long-Term U.S. Patents for Lead RNA Drug Candidates
PremiumCompany Announcements
PYC Therapeutics Wins Long-Term U.S. Patents for Lead RNA Drug Candidates
1M ago
PYC Therapeutics Strengthens Financial Leadership with New CFO Appointment
PremiumCompany AnnouncementsPYC Therapeutics Strengthens Financial Leadership with New CFO Appointment
1M ago
PYC Therapeutics Announces Lapse of 700,000 Unlisted Options
Premium
Company Announcements
PYC Therapeutics Announces Lapse of 700,000 Unlisted Options
2M ago
PYC’s VP-001 Eye Trial Reaches Phase 1 Finish Line, Setting Up the Next Investment Milestone
Premium
Company Announcements
PYC’s VP-001 Eye Trial Reaches Phase 1 Finish Line, Setting Up the Next Investment Milestone
3M ago
PYC
PYC Therapeutics Nears an Inflection Point With Completion of Its VP-001 Retinal Trial
PremiumCompany Announcements
PYC Therapeutics Nears an Inflection Point With Completion of Its VP-001 Retinal Trial
3M ago
PYC
PYC Therapeutics Resets CEO Pay to Sharpen Market Alignment and Performance Focus
PremiumCompany Announcements
PYC Therapeutics Resets CEO Pay to Sharpen Market Alignment and Performance Focus
3M ago
PYC
PYC Therapeutics outlines limits of data and risk profile in investor update
PremiumCompany Announcements
PYC Therapeutics outlines limits of data and risk profile in investor update
3M ago
PYC
PYC Therapeutics Cuts Option Overhang as Multiple Incentive Securities Lapse
PremiumCompany Announcements
PYC Therapeutics Cuts Option Overhang as Multiple Incentive Securities Lapse
3M ago
PYC
PYC to unveil early clinical data on first-in-class gene-targeted eye drugs at ARVO
PremiumCompany AnnouncementsPYC to unveil early clinical data on first-in-class gene-targeted eye drugs at ARVO
3M ago
PYC
PYC Therapeutics Issues New Shares Following Option Exercise and Lodges Cleansing Notice
Premium
Company Announcements
PYC Therapeutics Issues New Shares Following Option Exercise and Lodges Cleansing Notice
4M ago
PYC
PYC Therapeutics Lists Additional 250,000 Shares on ASX
Premium
Company Announcements
PYC Therapeutics Lists Additional 250,000 Shares on ASX
4M ago
PYC
PYC Therapeutics Advances Genetic Disease Pipeline After $600m Capital Raise
PremiumCompany Announcements
PYC Therapeutics Advances Genetic Disease Pipeline After $600m Capital Raise
4M ago
PYC
PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001
PremiumCompany Announcements
PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001
4M ago
PYC
PYC Therapeutics Wins Safety Nod to Advance ADOA Drug PYC-001 to Multi-Dose Trial
PremiumCompany Announcements
PYC Therapeutics Wins Safety Nod to Advance ADOA Drug PYC-001 to Multi-Dose Trial
4M ago
PYC
PYC Therapeutics CEO Increases Shareholding and Receives Major Option Grant
PremiumCompany Announcements
PYC Therapeutics CEO Increases Shareholding and Receives Major Option Grant
5M ago
PYC
PYC Therapeutics to Showcase PKD Drug Progress at World Nephrology Congress
PremiumCompany AnnouncementsPYC Therapeutics to Showcase PKD Drug Progress at World Nephrology Congress
5M ago
PYC
PYC Therapeutics Advances ADOA Drug PYC-001 With New Clinical Data and Ongoing Trial
Premium
Company Announcements
PYC Therapeutics Advances ADOA Drug PYC-001 With New Clinical Data and Ongoing Trial
5M ago
PYC
PYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating
Premium
Ratings
PYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating
5M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >